MaxCyte Appoints Cynthia
Collins to its Board of Directors
Rockville, MD, Oct. 15, 2024 -
MaxCyte, Inc., (Nasdaq: MXCT; LSE:
MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell-based therapeutics and innovative bioprocessing
applications, today
announced the appointment of Cynthia Collins to the Company's Board
of Directors as a non-executive director, effective October 14,
2024. Collins will serve on the
board's compensation committee. Following her appointment,
MaxCyte's total Board of Directors will increase to 10
members.
"I am pleased to welcome Cynthia to
MaxCyte's Board of Directors," said Maher Masoud, President and CEO
of MaxCyte. "Cynthia has extensive and impressive leadership
experience in the fields of cell therapy and genetic medicine that
will be invaluable to MaxCyte in the coming years. I look forward
to working alongside her to enable a growing set of next-generation
cell therapies as the premier cell engineering platform in our
industry."
Ms. Collins brings over 40 years of
experience in the biotechnology industry and cell and gene
medicines to MaxCyte, including her most recent role as Chief
Executive Officer of Editas Medicine, where she was involved in
dosing the first patient ever with an in-vivo gene modified
therapy. Previously, Ms. Collins served as Chief Executive Officer
of Human Longevity Inc., Chief Executive Officer/General Manager of
General Electric Healthcare's Cell Therapy and Lab Businesses, and
Chief Executive Officer of GenVec, Inc., a vaccine and gene therapy
company.
Currently, Ms. Collins serves as a
member of the Board of Directors of several healthcare companies,
including Alanis Therapeutics, Nutcracker Therapeutics, Poseida
Therapeutics (Nasdaq: PSTX), Certara (Nasdaq: CERT), DermTech (OTC:
DMTKQ), Draper Laboratory, and Panavance Therapeutics. She is also
a board member of the Foundation for mRNA Medicines.
Cynthia Collins holds a Bachelor of
Science degree in Microbiology from the University of Illinois,
Urbana and an MBA from The University of Chicago Booth School of
Business.
"I am honored to join MaxCyte's
Board of Directors, where I believe there is exceptional work being
done to propel the cell and genetic medicine industry forward,"
said Cynthia Collins. "I am excited to support the Company's growth
and innovation as they continue to help developers bring a new
class of therapies to market."
Regulatory Disclosures
In accordance with Rule 17, Schedule
Two paragraph (g) of the AIM Rules for Companies, Cynthia Lynne
Collins (66) holds, or has held, the following directorship or
partnerships in the last five years:
|
Current
|
Past 5 years
|
|
Alanis Therapeutics, Inc.
|
Triumvira Immunologics,
Inc.
|
|
Nutracker Therapeutics,
Inc.
|
Biocare Medical LLC
|
|
Panavance Therapeutics,
Inc.
|
Human Longevity, Inc.
|
|
The Charles Stark Draper Laboratory,
Inc.
|
Editas Medicine, Inc.
|
|
Poseida Therapeutics,
Inc.
|
ARM Foundation for Cell and Gene
Medicine
|
|
Certara, Inc.
|
|
|
DermTech Inc.
|
|
|
The Foundation for MRNA Medicines,
Inc.
|
|
Cynthia Collins, was previously
appointed as an independent director to the Board of DermTech, Inc.
on May 24, 2018. On June 18, 2024, the Company filed for Chapter 11
bankruptcy. On August 21, 2024 the US Bankruptcy Court for the
District of Delaware approved the sale of a substantial amount of
DermTech Inc.'s assets through a court-supervised
auction.
Save as disclosed above, there is no
further information to be disclosed pursuant to Rule 17 Schedule
Two paragraph (g) of the AIM Rules for Companies in respect of the
appointment of Cynthia Collins.
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been designed to support
the rapidly expanding cell therapy market and can be utilized
across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at
maxcyte.com and follow us on
X and
LinkedIn.
MaxCyte Contacts:
US IR
Adviser
Gilmartin
Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media
Relations
Spectrum
Science
Jordan Vines
jvines@spectrumscience.com
+1 540-629-3137
Nominated Adviser and Joint
Corporate Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR
Adviser
ICR
Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com